Role of taxanes in advanced prostate cancer
- 472 Downloads
Advanced prostate cancer is an androgen-dependent disease for which the initial treatment is an androgen deprivation maneuver. However, some primary resistances to hormonal treatment occur with increasing incidence throughout the evolution of the disease. The taxanes, docetaxel and cabazitaxel, exert their action at multiple levels at the tumor cell: besides inhibiting the mitosis and inducing the cell death, they induce the nuclear accumulation of FOXO1, a potent nuclear factor that acts against the activation of androgen receptor inhibiting the transcription of AR-V7 variant associated with the development of resistances to abiraterone and enzalutamide. Docetaxel, as first-line therapy, and cabazitaxel, as second-line therapy, have demonstrated to increase the survival in castration-resistant prostate cancer. The results from last studies either on high-risk localized disease or on androgen-sensitive tumors demonstrate the increasing role of taxanes at earlier states of prostate cancer.
KeywordsProstate cancer Docetaxel Cabazitaxel Androgen deprivation therapy AR splice variant
Medical writing assistance was provided by PIVOTAL S.L, funded by Sanofi. The authors are fully responsible for all content and editorial decisions for this manuscript. The authors indicate that they do not have any conflict of interests to declare.
Compliance with ethical standards
This article is a review of published studies, thus achievement of the patient Informed consent was not necessary.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr. 2013.
- 5.Sweeney C, Chen Y, Carducci MA, Liu G, Jarrard FD, Eisenberger MA, et al. Impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. 50th annual meeting of American Society of Clinical Oncology (June 2014). Abstract LBA2. 2015.Google Scholar
- 15.Sandler HM, Hu C, Rosenthal SA, Sartor O, Gomella LG, Amin M, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol. 2015;33 (suppl; abstr LBA5002).Google Scholar
- 16.James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Spears MR, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first overall survival results from STAMPEDE (NCT00268476). J Clin Oncol. 2015;33 (suppl; abstr 5001).Google Scholar
- 17.NCCN. Prostate cancer update. NCCN guidelines version 1. 2015.Google Scholar
- 19.Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. European association of urology: guidelines of prostate cancer 2012. http://www.uroweb.org/guidelines/online-guidelines. 2012.
- 22.Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64.PubMedGoogle Scholar
- 25.Oudard S, Kramer G, Creppy L, Loriot Y, Steinbjoern H, Holmberg M, et al. Management of metastatic castration-resistant prostate cáncer (mCRPC) after an initial good response to first-line docetaxel: a retrospective study on 270 patients. Eur J Cancer. 2011;47(Suppl 1):abstract 7049.Google Scholar
- 26.Bahl A, Oudard S, Tombal B, Ozguroglu M, Hansen S, Kocak I, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24(9):2402–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Chi KN, de Bono JS, Bahl A, Oudard S, Tombal B, Ozguroglu M, et al. Analysis of overall survival for patients with different prognostic risk factors treated with cabazitaxel and prednisone after docetaxel in the TROPIC trial. Ann Oncol. 2014;25(Suppl 4):iv255–79 (Poster 771P).Google Scholar
- 29.Perez Valderrama B, Mellado B, Juan MJ, Fernandez O, Fernandez-Parra E, Ochoa de Olza M, et al. Preliminary results of a phase II study of weekly cabazitaxel in “unfit” metastatic castration resistant prostate cancer (mCRPC) patients after docetaxel treatment (SOGUG-CABASEM trial). Ann Oncol. 2014;25(suppl 4):iv270 (783P).Google Scholar
- 31.Oudard S, Angelergues A, Gonzalez Maeso I, Delanoy N, Flechon A, Ozguroglu M, et al. Prognostic factors for survival and sequencing of life extending therapies in mCRPC patients in post-docetaxel setting. Ann Oncol. 2014;25(suppl 4):iv255–79 (789 P).Google Scholar
- 32.Sonpavde G, Bhor M, Hennessy D, Bhowmik D, Shen L, Nicacio L, et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration-resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer. 2015;13(4):309–18.CrossRefPubMedGoogle Scholar
- 33.Wissing MD, Coenen JL, van den BP, Westgeest HM, van den Eertwegh AJ, Van OI, et al. CAST: a retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Int J Cancer. 2015;136(6):E760–72.CrossRefPubMedGoogle Scholar
- 37.Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014;74(15):1544–50.CrossRefPubMedGoogle Scholar